Welcome to our dedicated page for Vyome Holdings news (Ticker: HIND), a resource for investors and traders seeking the latest updates and insights on Vyome Holdings stock.
Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome Therapeutics has completed its previously announced merger with ReShape Lifesciences (Nasdaq: RSLS). The combined entity, to be known as Vyome Holdings, will begin trading on Nasdaq under the new ticker symbol "HIND" on August 15, 2025. Vyome is a clinical-stage healthcare company focused on developing treatments for immuno-inflammatory and rare diseases in US and global markets.